Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 15, Issue 8, Pages 13299-13316Publisher
MDPI
DOI: 10.3390/ijms150813299
Keywords
urine biomarker; prostate cancer; PCA3; TMPRSS2-ERG gene fusion; PHI; radical prostatectomy; aggressiveness
Ask authors/readers for more resources
It has been suggested that urinary PCA3 and TMPRSS2: ERG fusion tests and serum PHI correlate to cancer aggressiveness-related pathological criteria at prostatectomy. To evaluate and compare their ability in predicting prostate cancer aggressiveness, PHI and urinary PCA3 and TMPRSS2: ERG (T2) scores were assessed in 154 patients who underwent radical prostatectomy for biopsy-proven prostate cancer. Univariate and multivariate analyses using logistic regression and decision curve analyses were performed. All three markers were predictors of a tumor volume >= 0.5 mL. Only PHI predicted Gleason score >= 7. T2 score and PHI were both independent predictors of extracapsular extension (>= pT3), while multifocality was only predicted by PCA3 score. Moreover, when compared to a base model (age, digital rectal examination, serum PSA, and Gleason sum at biopsy), the addition of both PCA3 score and PHI to the base model induced a significant increase (+12%) when predicting tumor volume >0.5 mL. PHI and urinary PCA3 and T2 scores can be considered as complementary predictors of cancer aggressiveness at prostatectomy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available